

-continued

<400> SEQUENCE: 10

```

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
1          5          10          15

Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
          20          25          30

Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
          35          40          45

Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
          50          55          60

Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
65          70          75          80

Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
          85          90          95

Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
          100          105          110

Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
          115          120          125

Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
          130          135          140

Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145          150          155          160

Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
          165          170          175

Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala
          180          185          190

```

What is claimed is:

1. A method for the treatment of a human patient with gastric cancer characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of a combination of an anti-ErbB2 antibody, or an antigen-binding fragment thereof, and a chemotherapeutic agent, to the human patient, wherein the chemotherapeutic agent is capecitabine or 5-fluorouracil, wherein the attending physician is provided with instructions including a warning that the treatment is not to be performed in combination with an anthracycline derivative and wherein said antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

2. The method of claim 1 wherein the chemotherapeutic agent is capecitabine.

35 3. The method of claim 2 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody, or an antigen-binding fragment thereof.

4. The method of claim 3 wherein the antibody is rhuMAb HER2.

40 5. The method of claim 1 further comprising the administration of a further chemotherapeutic agent.

6. The method of claim 5 wherein the further chemotherapeutic agent is cisplatin.

45 7. The method of claim 1 wherein efficacy is defined in terms of time to disease progression or response rate.

* * * * *